Madrigal Pharmaceuticals

ISIN US5588681057

 | 

WKN A2APCZ

Market cap (in EUR)
8,559 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR 8,559 m
WPA, EUR -11.40
KBV 16.4
K/W -
Dividendrendement 0.00%

Income statement (2025)

Omzet, EUR 850 m
Netto-inkomen, EUR -256 m
Winstmarge -30.08%

What ETF is Madrigal Pharmaceuticals in?

There are 4 ETFs which contain Madrigal Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Madrigal Pharmaceuticals is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weging Investeringsfocus Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.85%
Equity
United States
Health Care
Biotech
49
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
488
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.02%
Equity
North America
Social/Environmental
24
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.14%
Equity
United States
Small Cap
189
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.

Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.